Discovery of MK-1084: An Orally Bioavailable and Low-Dose KRASG12C Inhibitor
- 26 June 2024
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 67 (13) , 11024-11052
Abstract
Oncogenic mutations in the RAS gene account for 30% of all human tumors; more than 60% of which present as KRAS mutations at the hotspot codon 12. After decades of intense pursuit, a covalent inhibition strategy has enabled selective targeting of this previously "undruggable" target. Herein, we disclose our journey toward the discovery of MK-1084, an orally bioavailable and low-dose KRASG12C covalent inhibitor currently in phase I clinical trials (NCT05067283). We leveraged structure-based drug design to identify a macrocyclic core structure, and hypothesis-driven optimization of biopharmaceutical properties to further improve metabolic stability and tolerability.Keywords
This publication has 34 references indexed in Scilit:
- JDQ443, a Structurally Novel, Pyrazole-Based, Covalent Inhibitor of KRASG12C for the Treatment of Solid TumorsJournal of Medicinal Chemistry, 2022
- Fragment Optimization of Reversible Binding to the Switch II Pocket on KRAS Leads to a Potent, In Vivo Active KRASG12C InhibitorJournal of Medicinal Chemistry, 2022
- Phenols in Pharmaceuticals: Analysis of a Recurring MotifJournal of Medicinal Chemistry, 2022
- Discovery of AZD4625, a Covalent Allosteric Inhibitor of the Mutant GTPase KRASG12CJournal of Medicinal Chemistry, 2022
- Quantitative Systems Pharmacology Analysis of KRAS G12C Covalent InhibitorsCPT: Pharmacometrics & Systems Pharmacology, 2018
- Targeting KRAS Mutant Cancers with a Covalent G12C-Specific InhibitorCell, 2018
- RAS Proteins and Their Regulators in Human DiseaseCell, 2017
- A farnesyl transferase inhibitor suppresses TPA-mediated skin tumor development without altering hyperplasia in the ras transgenic Tg.AC mouseMolecular Carcinogenesis, 2000
- Ras oncoprotein inhibitors: The discovery of potent, ras nucleotide exchange inhibitors and the structural determination of a drug-protein complexBioorganic & Medicinal Chemistry, 1997
- Formation of heterocycles by the Mitsunobu reaction. Stereoselective synthesis of (+)-α-skytanthineTetrahedron Letters, 1996